|
1
|
Takara K, Sakaeda T and Okumura K: An
update on overcoming MDR1-mediated multidrug resistance in cancer
chemotherapy. Curr Pharm Des. 12:273–286. 2006.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Dong J, Yuan L, Hu C, Cheng X and Qin JJ:
Strategies to overcome cancer multidrug resistance (MDR) through
targeting P-glycoprotein (ABCB1): An updated review. Pharmacol
Ther. 249(108488)2023.PubMed/NCBI View Article : Google Scholar
|
|
3
|
To KKW, Huang Z, Zhang H, Ashby CR Jr and
Fu L: Utilizing non-coding RNA-mediated regulation of ATP binding
cassette (ABC) transporters to overcome multidrug resistance to
cancer chemotherapy. Drug Resist Updat. 73(101058)2024.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Kukal S, Guin D, Rawat C, Bora S, Mishra
MK, Sharma P, Paul PR, Kanojia N, Grewal GK, Kukreti S, et al:
Multidrug efflux transporter ABCG2: Expression and regulation. Cell
Mol Life Sci. 78:6887–6939. 2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Labialle S, Gayet L, Marthinet E, Rigal D
and Baggetto LG: Transcriptional regulators of the human multidrug
resistance 1 gene: Recent views. Biochem Pharmacol. 64:943–948.
2002.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ganesan M, Kanimozhi G, Pradhapsingh B,
Khan HA, Alhomida AS, Ekhzaimy A, Brindha GR and Prasad NR:
Phytochemicals reverse P-glycoprotein mediated multidrug resistance
via signal transduction pathways. Biomed Pharmacother.
139(111632)2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Takara K, Tsujimoto M, Ohnishi N and
Yokoyama T: Digoxin up-regulates MDR1 in human colon carcinoma
Caco-2 cells. Biochem Biophys Res Commun. 292:190–194.
2002.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Takara K, Tsujimoto M, Ohnishi N and
Yokoyama T: Effects of continuous exposure to digoxin on MDR1
function and expression in Caco-2 cells. J Pharm Pharmacol.
55:675–681. 2003.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Zambrano T, Hirata RDC, Hirata MH, Cerda Á
and Salazar LA: Statins differentially modulate microRNAs
expression in peripheral cells of hyperlipidemic subjects: A pilot
study. Eur J Pharm Sci. 117:55–61. 2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Liao D, Zhang W, Gupta P, Lei ZN, Wang JQ,
Cai CY, Vera AA, Zhang L, Chen ZS and Yang DH: Tetrandrine
interaction with ABCB1 reverses multidrug resistance in cancer
cells through competition with anti-cancer drugs followed by
downregulation of ABCB1 expression. Molecules.
24(4383)2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Xiao FY, Zhou FJ, Yuan F, Kuang W, Zhou G,
Zhou HH and Cao S: The potentiation of menadione on imatinib by
downregulation of ABCB1 expression. Clin Exp Pharmacol Physiol.
47:997–1004. 2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Pópulo H, Lopes JM and Soares P: The mTOR
signalling pathway in human cancer. Int J Mol Sci. 13:1886–1918.
2012.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Hasskarl J: Everolimus. Recent Results
Cancer Res. 211:101–123. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Shihab F, Christians U, Smith L, Wellen JR
and Kaplan B: Focus on mTOR inhibitors and tacrolimus in renal
transplantation: Pharmacokinetics, exposure-response relationships,
and clinical outcomes. Transpl Immunol. 31:22–32. 2014.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Gómez-Garduño J, León-Rodríguez R,
Alemón-Medina R, Pérez-Guillé BE, Soriano-Rosales RE,
González-Ortiz A, Chávez-Pacheco JL, Solorio-López E,
Fernandez-Pérez P and Rivera-Espinosa L: Phytochemicals that
interfere with drug metabolism and transport, modifying plasma
concentration in humans and animals. Dose Response.
20(15593258221120485)2022.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Fort-Casamartina E, Muñoz-Sanchez C,
Rigo-Bonnin RF, Del Valle-Celiz PM, Gonzalo-Diego N, Otero-Torres
S, Bleda-Perez C, Prats-Jimenez J and Fontanals-Martínez S: First
reported double drug-drug interaction in a cancer renal patient
under everolimus treatment: Therapeutic drug monitoring and review
of literature. Eur J Med Res. 28(202)2023.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Deng F, Sjöstedt N, Santo M, Neuvonen M,
Niemi M and Kidron H: Novel inhibitors of breast cancer resistance
protein (BCRP, ABCG2) among marketed drugs. Eur J Pharm Sci.
181(106362)2023.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Miklja Z, Yadav VN, Cartaxo RT, Siada R,
Thomas CC, Cummings JR, Mullan B, Stallard S, Paul A, Bruzek AK, et
al: Everolimus improves the efficacy of dasatinib in PDGFRα-driven
glioma. J Clin Invest. 130:5313–5325. 2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Takara K, Sakaeda T, Yagami T, Kobayashi
H, Ohmoto N, Horinouchi M, Nishiguchi K and Okumura K: Cytotoxic
effects of 27 anticancer drugs in HeLa and MDR1-overexpressing
derivative cell lines. Biol Pharm Bull. 25:771–778. 2002.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Takara K, Obata Y, Yoshikawa E, Kitada N,
Sakaeda T, Ohnishi N and Yokoyama T: Molecular changes to HeLa
cells on continuous exposure to cisplatin or paclitaxel. Cancer
Chemother Pharmacol. 58:785–793. 2006.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Takara K, Kitada N, Yoshikawa E, Yamamoto
K, Horibe S, Sakaeda T, Nishiguchi K, Ohnishi N and Yokoyama T:
Molecular changes to HeLa cells on continuous exposure to SN-38, an
active metabolite of irinotecan hydrochloride. Cancer Lett.
278:88–96. 2009.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Nakayama Y, Takara K, Minegaki T, Yamamoto
K, Omura T and Yano I: Induction of cross-resistance to ABCB1
substrates in venetoclax-resistant human leukemia HL60 cells.
Anticancer Res. 41:4239–4248. 2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Kitada N, Takara K, Minegaki T, Itoh C,
Tsujimoto M, Sakaeda T and Yokoyama T: Factors affecting
sensitivity to antitumor platinum derivatives of human colorectal
tumor cell lines. Cancer Chemother Pharmacol. 62:577–584.
2008.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Minegaki T, Takara K, Hamaguchi R,
Tsujimoto M and Nishiguchi K: Factors affecting the sensitivity of
human-derived esophageal carcinoma cell lines to 5-fluorouracil and
cisplatin. Oncol Lett. 5:427–434. 2013.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Lowry OH, Rosebrough NJ, Farr AL and
Randdall RJ: Protein measurement with the Folin phenol reagent. J
Biol Chem. 193:265–275. 1951.PubMed/NCBI
|
|
27
|
Okamoto I, Doi T, Ohtsu A, Miyazaki M,
Tsuya A, Kurei K, Kobayashi K and Nakagawa K: Phase I clinical and
pharmacokinetic study of RAD001 (everolimus) administered daily to
Japanese patients with advanced solid tumors. Jpn J Clin Oncol.
40:17–23. 2010.PubMed/NCBI View Article : Google Scholar
|
|
28
|
van Waterschoot RA and Schinkel AH: A
critical analysis of the interplay between cytochrome P450 3A and
P-glycoprotein: Recent insights from knockout and transgenic mice.
Pharmacol Rev. 63:390–410. 2011.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Nakayama Y, Enomoto D, Yamamoto K and
Takara K: Molecular characteristics of everolimus-resistant renal
cell carcinoma cells generated by continuous exposure to
everolimus. Anticancer Res. 43:4349–4357. 2023.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Nakayama Y, Ino A, Yamamoto K and Takara
K: Downregulation of ABCB1 in everolimus-resistant renal cell
carcinoma cell line. Anticancer Res. 44:2871–2876. 2024.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Rosolen D, Nunes-Souza E, Marchi R, Tofolo
MV, Antunes VC, Berti FCB, Fonseca AS and Cavalli LR: miRNAs action
and impact on mitochondria function, metabolic reprogramming and
chemoresistance of cancer cells: A systematic review. Biomedicines.
11(693)2023.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Zhu H, Wu H, Liu X, Evans BR, Medina DJ,
Liu CG and Yang JM: Role of MicroRNA miR-27a and miR-451 in the
regulation of MDR1/P-glycoprotein expression in human cancer cells.
Biochem Pharmacol. 76:582–588. 2008.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Zou Z, Zou R, Zong D, Shi Y, Chen J, Huang
J, Zhu J, Chen L, Bao X, Liu Y, et al: miR-495 sensitizes MDR
cancer cells to the combination of doxorubicin and taxol by
inhibiting MDR1 expression. J Cell Mol Med. 21:1929–1943.
2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Kazmierczak D, Jopek K, Sterzynska K,
Nowicki M, Rucinski M and Januchowski R: The profile of microRNA
expression and potential role in the regulation of drug-resistant
genes in cisplatin- and paclitaxel-resistant ovarian cancer cell
lines. Int J Mol Sci. 23(526)2022.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Safaei S, Amini M, Najjary S, Mokhtarzadeh
A, Bolandi N, Saeedi H, Alizadeh N, Javadrashid D and Baradaran B:
miR-200c increases the sensitivity of breast cancer cells to
doxorubicin through downregulating MDR1 gene. Exp Mol Pathol.
125(104753)2022.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Papadopoulos EI, Yousef GM and Scorilas A:
Cytotoxic activity of sunitinib and everolimus in Caki-1 renal
cancer cells is accompanied by modulations in the expression of
apoptosis-related microRNA clusters and BCL2 family genes. Biomed
Pharmacother. 70:33–40. 2015.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Xiang X, Zhuang L, Chen H, Yang X, Li H,
Li G and Yu J: Everolimus inhibits the proliferation and migration
of epidermal growth factor receptor-resistant lung cancer cells
A549 via regulating the microRNA-4328/phosphatase and tensin
homolog signaling pathway. Oncol Lett. 18:5269–5276.
2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Deng L, Jiang L, Lin XH, Tseng KF, Liu Y,
Zhang X, Dong RH, Lu ZG and Wang XJ: The PI3K/mTOR dual inhibitor
BEZ235 suppresses proliferation and migration and reverses
multidrug resistance in acute myeloid leukemia. Acta Pharmacol Sin.
38:382–391. 2017.PubMed/NCBI View Article : Google Scholar
|
